TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate a model of shared decision-making for asthma treatment, appropriate to the needs of African American, Latino, Chinese, and other Asian and low income Caucasian patients to adherence to asthma controller medications in a two-year randomized clinical trial in 302 minority and low-income adults, 18-70 years of age, with suboptimally controlled, persistent asthma, paralleling a simultaneous evaluation being conducted in 311 Caucasian and Asian/Pacific Island adults, (total n=613), and to examine psychological mechanisms mediating the effects of the intervention on adherence and of adherence on asthma outcomes.


Options:
A: Adherence rate to daily inhaled steroids, reported as the ratio of the sum of number of recorded over prescribed activation per day during the 28 days following the index visit.
B: N/A
C: number of subjects who achieved Total asthma Control: Period 2 (Up to Week 24)
D: Adherence to inhaled corticosteroid medication (12 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate a model of shared decision-making for asthma treatment, appropriate to the needs of African American, Latino, Chinese, and other Asian and low income Caucasian patients to adherence to asthma controller medications in a two-year randomized clinical trial in 302 minority and low-income adults, 18-70 years of age, with suboptimally controlled, persistent asthma, paralleling a simultaneous evaluation being conducted in 311 Caucasian and Asian/Pacific Island adults, (total n=613), and to examine psychological mechanisms mediating the effects of the intervention on adherence and of adherence on asthma outcomes.


Options:
A: N/A
B: Changes in Diabetes Self-management Behaviors as Measured by Summary of Diabetes Self-Care Activities (SDSCA) Scale (Baseline and 1 year); Changes in Minutes of Moderate Physical Activity (Baseline and 1 year); Changes in Minutes of Vigorous Exercise (Baseline and 1 year)
C: Change in systolic blood pressure; change in Hemoglobin A1C; change in low density lipoprotein (12 months)
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate a model of shared decision-making for asthma treatment, appropriate to the needs of African American, Latino, Chinese, and other Asian and low income Caucasian patients to adherence to asthma controller medications in a two-year randomized clinical trial in 302 minority and low-income adults, 18-70 years of age, with suboptimally controlled, persistent asthma, paralleling a simultaneous evaluation being conducted in 311 Caucasian and Asian/Pacific Island adults, (total n=613), and to examine psychological mechanisms mediating the effects of the intervention on adherence and of adherence on asthma outcomes.


Options:
A: The Number of Participants With a Differential Response to the Three Step-up Therapies Based on Fixed Threshold Criteria for the Following Three Asthma Control Measures: Use of Oral Prednisone for Acute Asthma Exacerbations, Asthma Control Days and FEV1. (Measured during the last 12 weeks of each 16-week treatment period)
B: N/A
C: Change (%) From Baseline in FcεRI (High-affinity IgE Receptor) Expression on Blood Basophils and Dendritic Cells After 16 Weeks of Treatment With Omalizumab as Compared With Placebo (Baseline and Week 16); Change (%) From Baseline in Mean Fluorescence Intensity of FcεRI After 16 Weeks of Treatment With Omalizumab as Compared With Placebo (Baseline and Week 16)
D: To evaluate distal airway function using high-resolution CT and lung function test (6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To evaluate a model of shared decision-making for asthma treatment, appropriate to the needs of African American, Latino, Chinese, and other Asian and low income Caucasian patients to adherence to asthma controller medications in a two-year randomized clinical trial in 302 minority and low-income adults, 18-70 years of age, with suboptimally controlled, persistent asthma, paralleling a simultaneous evaluation being conducted in 311 Caucasian and Asian/Pacific Island adults, (total n=613), and to examine psychological mechanisms mediating the effects of the intervention on adherence and of adherence on asthma outcomes.


Options:
A: Asthma Control (8 weeks (from Week 0 to Week 8))
B: Morning Peak Expiratory Flow
C: N/A
D: N/A

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: N/A
Brief Summary: To improve disease outcomes through reduction in secondhand tobacco smoke exposure of children with asthma


Options:
A: seven-day point prevalence smoking abstinence (28 weeks gestation and 12 months post-randomization)
B: N/A
C: Number of Symptom Free Days (Average Symptom Free Days, over 2 weeks, during peak asthma season (November-February))
D: change in child's hair nicotine concentration (baseline and 4-month follow-up); change in air nicotine concentration (baseline and 4-month follow-up)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Breastfeeding Among Methadone Maintained Women
Brief Summary: Methadone is a drug that offers significant therapeutic benefits to opiate dependent women who are pregnant. Currently, it is the treatment of choice for this group of people. The purpose of this study is to determine the amount of methadone in the breast milk of women who are breastfeeding and taking methadone for opiate addiction. In addition, this study will evaluate the effects of methadone on infant neurobehavior.


Options:
A: Length of Hospitalization (Up to 4 months)
B: methadone concentrations in breast milk (1-30 days after delivery); methadone concentrations in maternal plasma (1-30 days after delivery)
C: Cumulative dose of morphine required to treat NAS. (14 days of age); Highest dose of morphine required to treat NAS. (14 days of age)
D: Number of Participants Administered Morphine Treatment (Participants will be monitored for the duration of their newborn nursery stay, which is an expected mean of 7 days); Cumulative Pharmacological Treatment- Morphine Dose (Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days); Hospitalization Length of Stay (Day of life infants discharged home, which is an expected mean of 21 days.); Hospitalization Length of Stay for Untreated Infants (Day of life untreated infants discharged home, which is an expected mean of 21 days.); Hospitalization Length of Stay for Treated Infants (Day of life treated infants discharged home, which is an expected mean of 21 days.); Length of Pharmacological Treatment-Duration (Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days); Trajectory of Symptom Severity Among Treated Infants (Day of life infant started morphine treatment); Velocity of Weight Gain (Participants will be monitored for the duration of their hospitalization, which is an expected mean of 21 days); Neurobehavioral Outcomes Assessment (6 month and 12 months of life)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Naltrexone Augmentation of Nicotine Patch Therapy
Brief Summary: Naltrexone Augmentation of Nicotine Patch Therapy


Options:
A: N/A
B: Change From Baseline in Weight at 24 Weeks (baseline and 24 weeks)
C: To demonstrate an increase in smoking abstinence rate (12 months)
D: Continuous smoking abstinence rate (Weeks 9 to 12)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Trial to Reduce Hepatitis C Among Injection Drug Users
Brief Summary: The purpose of this study is to examine the efficacy of a brief motivational intervention on the cumulative incidence of Hepatitis C.


Options:
A: Hepatitis C seroconversion
B: prevalence of non-users of street opioid after one year of treatment will be compared between arms. (one year)
C: Opiate abstinence
D: 1. decrease in the number and proportion of times participants practiced vaginal or anal sex without a condom.; 2. decrease in the overall number of persons participants shared syringes or injection equipment with.; 3. decrease in the number and proportion of injections done with a syringe previously used by another person.; 4. decrease in the number and proportion of times participant used another person's equipment to prepare or divide drugs before injecting.

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: 4-week continuous quit rate (CQR) at Weeks 4-7 and 9-12 .
B: Will bupropion reduce relapse to smoking compared to placebo (52 weeks and 76 weeks)
C: Biochemically verified 7 day point prevalence abstinence from smoking.
D: Smoking behavior (after 5 hrs abstinence)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: Proportion of Daily Cigarettes Smoked in the 4 Hours After Receiving Methadone Dose (7 weeks)
B: Smoking behavior (after 5 hrs abstinence)
C: Quit Rate (Study weeks 6 through 9)
D: 4-week continuous quit rate (CQR) for Weeks 9-12

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: 7 day point prevalence of cigarette abstinence (End of trial (week 10))
B: Comparison of Prolonged Abstinence (up to12 weeks post-quit)
C: Smoking Abstinence (week 7, week 11 and week 24 after scheduled quit day)
D: Smoking behavior (after 5 hrs abstinence)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: N/A
B: Rating of urges to smoke 1-week after the target quit (1 week)
C: Smoking behavior (after 5 hrs abstinence)
D: Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 12 (12 weeks following treatment initiation); Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 24 (24 weeks following treatment initiation); Number of Participants With Reported 7-day Point Prevalence Abstinence at Week 52 (52 weeks following treatment initiation); Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 64 (64 weeks following treatment initiation); Number of Participants With Reported 7-day Point Prevalence Abstinence at Follow-up Week 104 (104 weeks following treatment initiation)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Transdermal Nicotine and Bupropion-SR in Schizophrenics (Study 2)
Brief Summary: Many individuals with schizophrenia smoke cigarettes but little is known about the factors that control smoking in people with schizophrenia. The purpose of this trial is to evaluate how bupropion, an antidepressant medication, affects smoking behaviors in individuals with schizophrenia who smoke.


Options:
A: Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) (weeks 8-11 after quit date)
B: The primary outcome is self-reported consecutive quit at 3 and 12 months following intervention. (3 and 12 month); Secondary outcomes are reduction in use, number of quit attempts at 3 and 12 months, and increases in readiness to quit. (3 and 12 months)
C: Smoking behavior (after 5 hrs abstinence)
D: Emotional Reactivity By Pharmacotherapy (Baseline to 1 month); Emotional Reactivity By Pharmacotherapy Moderated by DRD2 A1 Allele (Baseline to 1 month)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: CBT for Depression & Adherence in HIV Methadone Patients
Brief Summary: Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001).

Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.


Options:
A: Substance use (1 year); Unsafe sexual behavior (1 year)
B: CD4+ T lymphocytes (counts) (Pre-test and post-test)
C: Baby's health status (6 days after birth; 6 months after birth; 12 months after birth)
D: Percent Medication Adherence at 3-month Follow-up Assessment (3-month assessment); Percent Medication Adherence at 12-month Follow-up Assessment (12-month follow-up assessment)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: CBT for Depression & Adherence in HIV Methadone Patients
Brief Summary: Patients with HIV, depression, and opioid-dependence are at high risk for poor health outcomes. This is a two-arm randomized controlled trial of cognitive-behavioral therapy for depression and HIV medication adherence in patients with opioid dependence who are receiving methadone maintenance treatment. The project is based on our pilot work with close attention to NIDA guidelines for a staged approach to treatment development and testing (Rounsaville et al., 2001).

Depression is highly comorbid with both HIV infection and with opioid dependence. Depression and substance abuse are both associated with poor adherence to antiretroviral medications. Patients with HIV, depression, and opioid dependence are at high risk for poor health outcomes. Cognitive-behavioral therapy is the most widely studied and efficacious psychosocial intervention for depression; and research by the PI and others has shown that cognitive-behavioral interventions have been successful in promoting adherence to HIV medications.


Options:
A: The Symptom Check List 90 (SCL90-r), The Alcohol Use Disorder Identification Test (AUDIT), The Drug Use Disorder Identification Test (DUDIT). (Change during 6 and 12 months follow-up)
B: Alcohol consumption (12 weeks); Time to lapse (12 weeks); amount of alcohol consumption (12 weeks)
C: Stimulant drug use as measured by urine analysis (Treatment phase: 12 weeks (3 measurements a week), Follow Up Phase: 3 months (1 measuresment a month))
D: Percent Medication Adherence at 3-month Follow-up Assessment (3-month assessment); Percent Medication Adherence at 12-month Follow-up Assessment (12-month follow-up assessment)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Comparison of Prolonged Abstinence (up to12 weeks post-quit)
B: Rating of urges to smoke 1-week after the target quit (1 week)
C: Percentage of Participants With a Four-Week Continuous Quit Rate (CQR) (Week 9 through Week 12)
D: Expired-air Carbon Monoxide Confirmed Smoking Abstinence (52 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Expired-air Carbon Monoxide Confirmed Smoking Abstinence (52 weeks)
B: Prolonged Smoking Abstinence Rates at 12 Weeks in Cigarettes Smokers. (3 months); Point Prevalence Abstinence at 3 Months. (3 months)
C: Biochemically-confirmed 7-Day Point-Prevalence Abstinence at 26 Weeks (Assessed 26 weeks after the target quit day.)
D: Proportion of Daily Cigarettes Smoked in the 4 Hours After Receiving Methadone Dose (7 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Smoking Abstinence - Serum/Urine Measurements (Week 12); Smoking Abstinence - Number of Cigarettes Smoked (Week 12); Smoking Abstinence - Exhaled Carbon Monoxide (Week 12)
B: Expired-air Carbon Monoxide Confirmed Smoking Abstinence (52 weeks)
C: Quit Rate (4 months)
D: Cotinine-validated 7-day point prevalence tobacco abstinence at 1 year follow-up; Cotinine-validated 7-day point prevalence tobacco abstinence at 3 month follow-up (end of treatment)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Prevention in relapse (Up to 6 months)
B: Expired-air Carbon Monoxide Confirmed Smoking Abstinence (52 weeks)
C: Continuous abstinence Weeks 13 -24.
D: Change in sputum eosinophile-% from >1% to normal or neutrophile-% from >61% to normal, from baseline (week 0) to week 12. (Time frame for primary outcome: 0-12 weeks (total study duration 24 weeks))

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Selegiline Patch for Treatment of Nicotine Dependence
Brief Summary: Relapse to smoking is a common problem affecting smokers who seek treatment. The purpose of this study is examine whether selegiline, given in the form of a skin patch, is effective in stopping smoking.


Options:
A: Number of Responders With Carbon Monoxide (CO) Confirmed 4-week Continuous Quit Rate (CQR) for Last 4 Weeks of Treatment (Trtmt) (weeks 9 through 12)
B: 4 week Continuous Quit Rate ( 4 week CQR ) for weeks 9 -12
C: Smoking Abstinence (12 months)
D: Expired-air Carbon Monoxide Confirmed Smoking Abstinence (52 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder
Brief Summary: This study will examine the effectiveness of combining cognitive therapy with enriched usual care for preventing subsequent suicide attempts in people with a drug dependence who have recently attempted suicide.


Options:
A: Dissociation Tension Scale (DSS), a reliable and valid self-rating instrument to assess dissociative experiences and inner tension during the last 24 hours (Stiglmayr et al. 2001) (Oct. 1998-Oct 2001)
B: Suicidal Attempts (Months 1, 3, 6, 12, 18, and 24)
C: Change in Autonomous and Controlled Motivation (From baseline until 3 months following the completion of the 1-day intervention (i.e., average of 3 months))
D: Time to Fatal or Non-fatal Suicide Attempt or Self-Harm (18 Months after randomization)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder
Brief Summary: This study will examine the effectiveness of combining cognitive therapy with enriched usual care for preventing subsequent suicide attempts in people with a drug dependence who have recently attempted suicide.


Options:
A: Suicidal Attempts (Months 1, 3, 6, 12, 18, and 24)
B: Change in self-injury attentional bias as measured by a Dot Probe Paradigm (The Dot Probe Paradigm will be administered immediately preceding the mindfulness or control conditions and immediately following the mindfulness or control conditions)
C: Beck scale for suicidal ideation (six months)
D: Repetition of self-harm (Three months); Change scores on the Suicide Behaviors Questionnaire from baseline (Baseline and three months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Cognitive Therapy for Suicide Attempters With Drug Dependence Disorder
Brief Summary: This study will examine the effectiveness of combining cognitive therapy with enriched usual care for preventing subsequent suicide attempts in people with a drug dependence who have recently attempted suicide.


Options:
A: Suicide Events (1 year)
B: Suicide Mortality Rates (Study Completion (2 years))
C: adolescent alcohol use and binge drinking (any, number of days, number of related problems) (change from baseline to 6 months (prior 3 months)); adolescent suicidal ideation and behavior (severity of suicidal ideation and presence of any suicidal ideation or suicidal behavior) (change from baseline to 6 months (prior month to 6 months)); adolescent HIV risk behavior (any sexual behavior, number of sexual partners, number of unprotected sexual acts) (change from baseline to 6 months (prior 3 months)); adolescent marijuana use (any use, number of days, related problems) (change from baseline to 6 months (prior 3 months)); adolescent alcohol use and binge drinking (any, number of days, number of related problems) (change from baseline to 12 months (prior 3 months)); adolescent suicidal ideation and behavior (severity of suicidal ideation and presence of any suicidal ideation or suicidal behavior) (change from baseline to 12 months (prior month to 6 months)); adolescent HIV risk behavior (any sexual behavior, number of sexual partners, number of unprotected sexual acts) (change from baseline to 12 months (prior 3 months)); adolescent marijuana use (any use, number of days, related problems) (change from baseline to 12 months (prior 3 months))
D: Suicidal Attempts (Months 1, 3, 6, 12, 18, and 24)

Answer: D